Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22049973 | 0.79 | PRMT6 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL29022158 | 0.78 | PRMT3 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL14640362 | 0.77 | L3MBTL1 (0.46) | KCNH2HRH3POLB | |
| SCHEMBL14944939 | 0.77 | KCNH2 (0.40) | KCNH2HRH3CCR3 | |
| SCHEMBL2603270 | 0.76 | SLC18A2 (0.50) | — | |
| SCHEMBL13995045 | 0.76 | SLC18A2 (0.50) | — | |
| SCHEMBL5355075 | 0.75 | TACR1 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL2603288 | 0.75 | SLC18A2 (0.49) | — | |
| SCHEMBL20841376 | 0.71 | KCNH2 (0.47) | KCNH2HRH3 | |
| SCHEMBL18870565 | 0.70 | MC4R (0.44) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | PRMT3 828/4885CARM1 1328/4885PRMT6 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.